Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

SILVER SPRING, Md., July 25, 2013 /PRNewswire/ --  

  • Total Revenues of $280.6 million
  • Earnings per Share of $1.60 per Basic Share or $1.52 per Diluted Share
  • Earnings Before Non-Cash Charges of $3.29 per Basic Share, or $3.11 per Diluted Share
  • United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2013.

    "I am very pleased with our second quarter results and the continued strong growth of our core business," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "We continue to assist more patients than ever to manage pulmonary arterial hypertension while we also continue to develop new possibilities for the future, such as the implantable Remodulin pump."

    Total revenues for the quarter ended June 30, 2013 were $280.6 million, up from $225.6 million for the quarter ended June 30, 2012. Net income for the quarter ended June 30, 2013 was $79.9 million or $1.60 per basic share, compared to $72.3 million or $1.37 per basic share for the same quarter in 2012. Gross margin from sales was $245.2 million for the quarter ended June 30, 2013, compared to $192.2 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended June 30, 2013 were $163.7 million, compared to $127.7 million for the same quarter in 2012.(1)

    See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.Financial Results for the Three Months Ended June 30, 2013 Revenues

    The table below summarizes the components of net revenues (dollars in thousands):Three Months Ended June 30,Percentage Change20132012Cardiopulmonary products:Remodulin

    $

    '/>"/>
    SOURCE United Therapeutics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
    2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
    3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
    4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
    5. Prevagen® is the Number One Branded Memory Supplement in the United States
    6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
    7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
    8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
    9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
    10. SoundConnect Announces Lync Release in the United States
    11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... (PRWEB) August 19, 2014 In November 2012, ... Benefit Risk Evaluation Report (PBRER) in a new PSUR – ... post-authorization safety benefit-risk profile of a drug. Adopted in many ... , Present a comprehensive and critical analysis of ... , Highlight any new evidence of the potential ...
    (Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
    (Date:8/18/2014)... 2014 Deep Research Report on ... and in-depth research report on the China Linalool ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
    (Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
    Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3
    ... Crystal Research Associates, LLC announced today that it ... Inc. (NYSE Amex: CUR ). The full ... .Neuralstem, Inc. ("Neuralstem" or "the Company") is a ... stem cells to treat central nervous system (CNS) diseases. ...
    ... /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS;,Nasdaq: PXSL ) ... afternoon of Wednesday 8th April 2009. Dr Alan Robertson ... quarter and answer,investor questions. , The ... 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West ...
    ... April 6 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the ... venture to Spectrum for approximately $16.5 million that closed ... on March 2, 2009, related to this transaction, and ...
    Cached Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 3CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 2CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 3
    (Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
    (Date:8/19/2014)... used in supermarkets to encourage healthier spending habits? A ... that very question by tracking the purchasing records in ... to rate the nutritional value of foods for sale. ... David Just, PhD, and Brian Wansink PhD, author of ... over 150 Hannaford Supermarkets in the Northeastern United States ...
    (Date:8/19/2014)... In many parts of the world, leprosy and ... new cases of leprosy per year, with nearly ... The currently available century-old vaccine Bacille Calmette-Guerin, or ... and leprosy, so a more potent vaccine is ... have found a stronger weapon against both diseases., ...
    Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
    ... research from Rice University, Baylor College of Medicine (BCM) and ... of flow in the small blood vessels of the heart ... and form dangerous blood clots. The scientists were surprised to ... shape for up to five hours before returning to their ...
    ... Department of Energy,s National Renewable Energy Laboratory (NREL) eases and ... industry: determining cell wall chemistry to find plants with ideal ... thoroughly analyze hundreds of biomass samples a day and give ... pursuing. Analysis of a sample that previously took two weeks ...
    ... VA As the Colorado River winds through the Colorado ... of sediment. This sediment which once left the river,s ... Colorado "the reddish river" is a vital component to ... of the Hoover and Glen Canyon dams, which trap the ...
    Cached Biology News:Stressed proteins can cause blood clots for hours 2Stressed proteins can cause blood clots for hours 3Biomass analysis tool is faster, more precise 2Biomass analysis tool is faster, more precise 3Biomass analysis tool is faster, more precise 4Biomass analysis tool is faster, more precise 5
    ... Isolated Sequence) siRNA Test System is designed ... of a potential of any DNA sequence ... RNA interference (RNAi). Current computer-based RNAi target ... probability of selected sequence to be a ...
    ... Stabilizer is a is a bovine protein-free ... product is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2. ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ...
    ... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
    ... This mounting medium is specifically formulated for ... which have been stained with immunohistochemical methods ... ideal for use with chromogens, such as ... organic solvents. Faramount dries completely when slides ...
    Biology Products: